ABSTRACT
Dear Editor, in recent years there has been an increase in the number of new cases of cancer. This increase, in part, is closely related to the increase in average life expectancy, as well as more accurate diagnostic techniques and well-defined screening programs. [...].
Subject(s)
COVID-19 , Health Promotion , Men's Health , Prostatic Neoplasms/prevention & control , Testicular Neoplasms/prevention & control , Foundations , Humans , MaleABSTRACT
The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation.
Subject(s)
COVID-19 , Drug Development/economics , Drug Development/trends , Drug Industry/economics , Drug Industry/trends , Investments , Pandemics , Europe , Foundations , ResearchSubject(s)
COVID-19/pathology , Dermatology/organization & administration , Hotlines/statistics & numerical data , Skin Diseases/pathology , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/psychology , Foundations/organization & administration , Health Services Accessibility/trends , Hotlines/trends , Humans , Ireland/epidemiology , Nurse's Role , SARS-CoV-2/genetics , Skin Diseases/diagnosis , Skin Diseases/epidemiologyABSTRACT
The reported incidence of COVID-19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID-19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID-19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti-COVID-19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS-CoV2 and patients affected by metabolic syndrome constitute a high-risk group for COVID-19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non-living virus anti-SARS-CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.
Subject(s)
COVID-19/complications , Hidradenitis Suppurativa/complications , Hidradenitis Suppurativa/drug therapy , SARS-CoV-2 , Adalimumab/therapeutic use , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/immunology , COVID-19 Vaccines/pharmacology , Cohort Studies , Disease Susceptibility , Europe , Foundations , Hidradenitis Suppurativa/immunology , Humans , Incidence , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Metabolic Syndrome/complications , Metabolic Syndrome/immunology , Pandemics , Severity of Illness IndexABSTRACT
The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap) survey was developed and sent to network sites to monitor and understand the impact on research teams, ongoing and anticipated clinical research, and specific clinical and research procedures. Key findings indicated an early impact on participant enrollment, research team stability, and procedures such as spirometry and sputum induction. These trends steadily improved over the months as research activities began to recover across the TDN. While SARS-CoV-2 created a significant challenge it also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation.
Subject(s)
Biomedical Research/organization & administration , COVID-19/epidemiology , Cystic Fibrosis/therapy , COVID-19/prevention & control , COVID-19/transmission , Foundations , Humans , Research Design , Spirometry , Surveys and QuestionnairesSubject(s)
Coronavirus Infections/epidemiology , Delivery of Health Care/organization & administration , Developed Countries/economics , Disaster Planning/trends , Pneumonia, Viral/epidemiology , Vulnerable Populations , Africa/epidemiology , COVID-19 , Coronavirus Infections/economics , Coronavirus Infections/transmission , Delivery of Health Care/economics , Delivery of Health Care/standards , Developed Countries/statistics & numerical data , Disease Outbreaks , Epidemiological Monitoring , Foundations/economics , Global Health , Hemorrhagic Fever, Ebola/drug therapy , Hemorrhagic Fever, Ebola/economics , Hemorrhagic Fever, Ebola/epidemiology , Humans , Pandemics/economics , Pneumonia, Viral/economics , Pneumonia, Viral/transmission , Vulnerable Populations/statistics & numerical data , World Health OrganizationSubject(s)
Betacoronavirus/immunology , Clinical Laboratory Techniques , Coronavirus Infections/epidemiology , Health Personnel/statistics & numerical data , Hospitals, Voluntary/statistics & numerical data , Pandemics , Pneumonia, Viral/epidemiology , Adult , Antibodies, Viral/blood , COVID-19 , COVID-19 Testing , Coronavirus Infections/diagnosis , Female , Foundations , France/epidemiology , Humans , Immunoglobulin G/blood , Male , Middle Aged , Pneumonia, Viral/diagnosis , SARS-CoV-2 , Seroepidemiologic StudiesSubject(s)
Coronavirus Infections/ethnology , Foundations , Healthcare Disparities , Pneumonia, Viral/ethnology , Betacoronavirus , COVID-19 , Charities , Financing, Organized , Foundations/economics , Foundations/history , Fund Raising , Healthcare Disparities/ethnology , History, 19th Century , Humans , Pandemics , SARS-CoV-2 , United States/epidemiologyABSTRACT
The COVID-19 pandemic has had a significant impact on many aspects of head and neck cancer (HNC) care. The uncertainty and stress resulting from these changes has led many patients and caregivers to turn to HNC advocacy groups for guidance and support. Here we outline some of the issues being faced by patients with HNC during the current crisis and provide examples of programs being developed by advocacy groups to address them. We also highlight the increased utilization of these organizations that has been observed as well as some of the challenges being faced by these not-for-profit groups as they work to serve the head and neck community.